Tvardi Therapeutics
TVRD
Tvardi Therapeutics (TVRD) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$1.00
- EPS estimate
- −$0.68
- EPS surprise
- −46.39%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 14, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 14, 2025 | −$0.68 | −$1.00 | −46.39% | $0.00 | SEC |
| Q1 2025 | May 13, 2025 | −$0.59 | −$3.22 | −450.43% | $2.6M | SEC |
| Q4 2024 | Mar 11, 2025 | −$7.08 | −$1.68 | +76.27% | $0.00 | SEC |
| Q1 2024 | May 13, 2024 | −$14.33 | −$20.16 | −40.70% | $2.1M | SEC |
| Q4 2023 | Mar 4, 2024 | −$16.06 | −$21.24 | −32.29% | $3.0M | SEC |
| Q3 2023 | Nov 13, 2023 | −$18.72 | −$18.72 | +0.00% | $4.9M | SEC |
| Q2 2023 | Aug 7, 2023 | −$19.38 | −$20.88 | −7.74% | $6.9M | SEC |
| Q1 2023 | May 15, 2023 | −$18.48 | −$17.64 | +4.55% | $6.2M | SEC |
| Q4 2022 | Mar 6, 2023 | −$12.34 | −$20.16 | −63.33% | $3.3M | SEC |
| Q3 2022 | Nov 7, 2022 | −$14.81 | −$15.48 | −4.51% | $10.8M | — |
| Q2 2022 | Aug 8, 2022 | −$9.41 | −$2.88 | +69.40% | $23.0M | — |
| Q1 2022 | May 9, 2022 | −$19.85 | −$18.72 | +5.70% | $4.8M | — |
| Q4 2021 | Mar 1, 2022 | −$18.41 | −$22.68 | −23.18% | $821,000.00 | — |
| Q3 2021 | Nov 8, 2021 | −$13.91 | −$0.72 | +94.82% | $20.3M | — |
| Q2 2021 | Aug 9, 2021 | −$19.74 | −$21.96 | −11.25% | $0.00 | — |
| Q1 2021 | May 10, 2021 | −$20.64 | −$16.92 | +18.02% | $1.9M | — |
| Q4 2020 | Feb 25, 2021 | $13.11 | $57.24 | +336.47% | $112.1M | — |
| Q3 2020 | Nov 9, 2020 | −$21.50 | −$12.60 | +41.39% | $9.3M | — |
| Q2 2020 | Aug 10, 2020 | −$23.97 | −$19.44 | +18.88% | $5.6M | — |
| Q1 2020 | May 11, 2020 | −$21.69 | −$22.32 | −2.90% | $8.1M | — |
Quarterly revenue
Frequently asked questions
When did Tvardi Therapeutics (TVRD) last report earnings?
Tvardi Therapeutics last reported on Aug 14, 2025, covering fiscal Q2 2025.
Did TVRD beat earnings estimates?
No. Tvardi Therapeutics reported EPS of −$1.00 for Q2 2025 against a −$0.68 estimate — a 46.39% miss.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.